MTDH

Across TCGA pan-cancer cohorts, MTDH mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MTDH data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MTDH mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MTDH expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where MTDH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.736	1.000	.001	50	view →
PDAC	OS	Quartile	All	0.956	0.561	.006	14	view →
LUAD	OS	Quartile	III,IV	0.839	0.188	.002	11	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
GBM	OS	Quartile	All	0.694	0.856	.035	3	view →
HNSC	DFS	Median	II,III,IV	0.904	0.984	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MTDH–CCRCC (OS)

Open the CCRCC breakdown →